Yoram Harth - Endymed Founder, Director & Chief Medical Officer
| ENDY Stock | 325.00 5.80 1.75% |
Director
Dr. Yoram Harth serves as Founder Director and Chief Medical Officer at Endymed Ltd since January 2 2012. He is a dermatologist and an expert in product innovation. His work experience includes the following roles founder president and medical director of CureLight Medical Ltd. and research fellow at Columbia Presbyterian Hospital in New York City and a faculty member of the American Academy of Dermatology since 2012.
| Age | 56 |
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Phone | 855 363 9633 |
| Web | https://www.endymed.com |
Endymed Management Efficiency
The company has return on total asset (ROA) of 0.0385 % which means that it generated a profit of $0.0385 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2146 %, meaning that it generated $0.2146 on every $100 dollars invested by stockholders. Endymed's management efficiency ratios could be used to measure how well Endymed manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Edith Lusky | Bezeq Israeli Telecommunication | 66 | |
| Joshua Shemer | Compugen | 63 | |
| Michael Anghel | BioLine RX | 78 | |
| Abraham Havron | Kamada | 71 | |
| Ziv Kop | Evogene | 46 | |
| Oded Shoseyov | Evogene | 62 | |
| Tuvia Shoham | Kamada | 70 | |
| Gwen Melincoff | Kamada | 67 | |
| Jonathan Hahn | Kamada | 32 | |
| Adina Makover | Evogene | 66 | |
| Mali Zeevi | BioLine RX | 40 | |
| Mordechai Keret | Bezeq Israeli Telecommunication | 60 | |
| Adrian Percy | Evogene | N/A | |
| Orly Guy | Bezeq Israeli Telecommunication | 56 | |
| BarbaraJean Bormann | BioLine RX | 55 | |
| Ziv Kop | Kamada | 43 | |
| Ilan Biran | Bezeq Israeli Telecommunication | 70 | |
| Simcha Sadan | Evogene | 72 | |
| Ami Barlev | Bezeq Israeli Telecommunication | 39 | |
| Sanford Zweifach | Compugen | 60 | |
| Raphael Hofstein | BioLine RX | 67 | |
Management Performance
| Return On Equity | 0.21 | |||
| Return On Asset | 0.0385 |
Endymed Leadership Team
Elected by the shareholders, the Endymed's board of directors comprises two types of representatives: Endymed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Endymed. The board's role is to monitor Endymed's management team and ensure that shareholders' interests are well served. Endymed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Endymed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amir Schori, Vice President - Business Development | ||
| Lee Gabay, Controller | ||
| Ben Feldman, CFO | ||
| Rami Aviram, Vice President - Finance | ||
| Yossi CPA, Chief Officer | ||
| Yoram Hert, CEO, Endymed Medical Ltd. | ||
| Amiram Goldman, External Director | ||
| Eran Naor, External Director, Independent Director | ||
| Ronen Zadok, External Director | ||
| Amy Kamin, CEO of EndyMed USA | ||
| Elad Magal, CEO | ||
| Yoram Harth, Founder, Director & Chief Medical Officer | ||
| Yuan Yibing, Director | ||
| Sima Weissman, VP RD | ||
| Batsheva Elran, Director | ||
| Sima Witman, Vice President - Research & Development | ||
| Oren Maymon, Vice President - Operations | ||
| Lior Cohen, Vice President of Sales | ||
| Yosef BarOn, CEO | ||
| Joseph Levtzler, Clinical VP | ||
| Atzmon Shlush, Vice President - Operations | ||
| Eran Ishay, Vice President - Research & Development | ||
| Jan Jingran, Director | ||
| Sharon Dovev, Director of Marketing | ||
| Lior Vider, External Director | ||
| Daniel Lishinsky, Vice President - Research & Development | ||
| Idan Alfa, Finance Director | ||
| Yocheved Dvir, Director | ||
| Annie Jin, Director | ||
| Lee Roth, Finance Director | ||
| Zvika Lifschitz, Vice President - Finance | ||
| Ofer Zvi, Director | ||
| Bill Scott, Pres Inc | ||
| Daniel Lischinsky, Founder and VP of RandD | ||
| Moshe Cohen, Internal Auditor | ||
| Frank Iannelli, Corporate Executive | ||
| Amir Ganun, VP Marketing |
Endymed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Endymed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.21 | |||
| Return On Asset | 0.0385 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 1.85 M | |||
| Shares Outstanding | 13.76 M | |||
| Shares Owned By Insiders | 58.11 % | |||
| Price To Book | 0.70 X | |||
| Price To Sales | 1.52 X | |||
| Revenue | 21.78 M |
Pair Trading with Endymed
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Endymed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Endymed will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Endymed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Endymed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Endymed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Endymed to buy it.
The correlation of Endymed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Endymed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Endymed moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Endymed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Endymed. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Endymed Stock analysis
When running Endymed's price analysis, check to measure Endymed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Endymed is operating at the current time. Most of Endymed's value examination focuses on studying past and present price action to predict the probability of Endymed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Endymed's price. Additionally, you may evaluate how the addition of Endymed to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |